RAS(ON) Inhibitor Daraxonrasib Demonstrates Promising Outcomes in Phase 1/2 Trial for Advanced Pancreatic Cancer
In a groundbreaking clinical milestone, the novel targeted RAS inhibitor daraxonrasib has demonstrated both safety and promising efficacy in a ...
